SCHEMBL243605

SCHEMBL243605

CCCCC(N)C(=O)NO

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 11/20 0.63
SLC15A1 P46059 1/20 0.63
CA1 P00915 2/20 0.59
CA2 P00918 2/20 0.59
DPP9 Q86TI2 8/20 0.58
DPP8 Q6V1X1 8/20 0.58
DPP4 P27487 5/20 0.58
HDAC7 Q8WUI4 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
HDAC9 Q9UKV0 1/20 0.50
HDAC5 Q9UQL6 1/20 0.50
GNAI3 P08754 1/20 0.50
GNAO1 P09471 1/20 0.50
GNAI1 P63096 1/20 0.50
RRM1 P23921 1/20 0.49
METAP1 P53582 1/20 0.47
SLC1A3 P43003 1/20 0.46
SLC1A2 P43004 1/20 0.46
SLC1A1 P43005 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5574688 0.92 GNAI3 (0.60) DPP7SLC15A1CA1CA2DPP9
SCHEMBL30117075 0.86
SCHEMBL247697 0.86
SCHEMBL4926973 0.84 DPP7 (0.51) DPP7SLC15A1CA1CA2DPP9
SCHEMBL3248464 0.83 DPP7 (0.63) DPP7SLC15A1CA1CA2DPP9
SCHEMBL15186165 0.83 DPP7 (0.63) DPP7SLC15A1CA1CA2DPP9
SCHEMBL30541580 0.83 DPP7 (0.63) DPP7SLC15A1CA1CA2DPP9
SCHEMBL4928010 0.81 DPP7 (0.45) DPP7SLC15A1CA1CA2DPP9
SCHEMBL24907137 0.81 DPP7 (0.72) DPP7SLC15A1CA1CA2DPP9
SCHEMBL11221181 0.80 GSR (0.50) DPP7SLC15A1DPP9DPP8DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140045943-A1 Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof NAUREX, INC. (US) 2014-02-13 US disclosed
US-20120004309-A1 Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof KHAN AMIN (US) 2012-01-05 US disclosed
WO-2010065709-A2 HYDROXAMIC ACID DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF KHAN AMIN (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004309-A1 Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof GLS, HGFAC, AADAC DPP7 338/4885SLC15A1 1020/4885CA1 369/4885
US-20140045943-A1 Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof GLS, HGFAC, AADAC DPP7 338/4885SLC15A1 1020/4885CA1 369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.